Specialty Nuerology, PC — Englewood, Colorado

Specialty Nuerology, PC is a clinical research site located in Englewood, Colorado, United States 80113.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

Specialty Nuerology, PC has participated in 1 clinical trials.

Therapeutic areas: Epilepsy.

Sponsors: Sumitomo Pharma America, Inc..

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Englewood

Browse all research sites in Colorado · View every site in Englewood

• University Park Hematology Oncology
• University of Colorado Health Sciences Ctr
• Jewish Hospital
• Rocky Vista University
• Swedish Hospital
• University of Colorado | Steadman Hawkins Clinic Denver
• University Parks Hematology/Oncology
• Steadman Hawkins Clinic, University of Colorado Denver
• University of Colorado/Craig Hospital
• Craig Hospital
• Swedish Medical Center
• Mountain Blue Cancer Care Center - Swedish

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Specialty Nuerology, PC?

Specialty Nuerology, PC has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Specialty Nuerology, PC conducted?

Specialty Nuerology, PC has 1 clinical trials on record. Their work covers Epilepsy.

Is Specialty Nuerology, PC accredited by Crixeo Clinical Trials?

Specialty Nuerology, PC has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Specialty Nuerology, PC?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.